Ketamine Therapy and Cannabis: What Patients Need to Know

Cannabis use is increasingly common among patients seeking ketamine therapy, and I believe this topic deserves a frank, non-judgmental conversation. Whether you use cannabis medicinally for pain, anxiety, or sleep, or recreationally for relaxation, understanding how it interacts with ketamine therapy is important for your safety and treatment success. I am going to share what we know, what we do not know, and my honest clinical perspective.

The Honest Reality: We Have Limited Data

I want to start with intellectual honesty. There are no large, rigorous clinical trials specifically studying the interaction between cannabis and ketamine therapy for depression. The research that exists consists of preclinical studies, case reports, and mechanistic reasoning based on what we understand about how each substance affects the brain.

This does not mean we know nothing. It means that my recommendations are based on the best available evidence, clinical experience, pharmacological reasoning, and the precautionary principle. Where I am speculating or extrapolating rather than citing definitive research, I will say so.

How Cannabis and Ketamine Interact in the Brain

Both cannabis and ketamine affect brain function, but through different primary mechanisms.

Cannabis works primarily through the endocannabinoid system, binding to CB1 and CB2 receptors throughout the brain and body. THC (tetrahydrocannabinol) is the psychoactive component responsible for the "high," while CBD (cannabidiol) has more subtle effects without significant psychoactivity.

Ketamine works primarily through the glutamate system, blocking NMDA receptors and triggering a cascade that promotes synaptic growth and neuroplasticity.

While these are distinct systems, they are not isolated from each other. The endocannabinoid and glutamate systems interact at multiple points. Cannabinoid receptors are present on glutamatergic neurons, and endocannabinoid signaling can modulate glutamate release. This means cannabis use has the potential to influence the very neurochemical processes that make ketamine therapy effective.

Specific Concerns With THC

THC raises several concerns in the context of ketamine therapy:

Cardiovascular effects. Both THC and ketamine can increase heart rate. THC also affects blood pressure in complex, dose-dependent ways -- it can cause initial hypertension followed by hypotension. Combined with ketamine's tendency to temporarily raise blood pressure, the cardiovascular profile becomes less predictable. For patients with any cardiovascular risk factors, this unpredictability is concerning. Our safety protocols include blood pressure monitoring, but adding variables that complicate cardiovascular response is not ideal.

Enhanced dissociation and psychological unpredictability. THC can intensify dissociative experiences and alter the quality of the ketamine session in ways that may not be therapeutically productive. Some patients report increased anxiety or paranoia when combining cannabis with dissociative states. Others report confusion about what is a ketamine effect versus a cannabis effect, making it harder to calibrate treatment.

Impact on neuroplasticity. This is where my concern is greatest, even though the evidence is preliminary. Some research suggests that chronic THC use may impair certain aspects of neuroplasticity -- the very mechanism that makes ketamine therapy work. If cannabis is dampening the brain's ability to form new synaptic connections, it could undermine the therapeutic benefit you are investing time and money to achieve.

Sleep architecture disruption. While many patients use cannabis to fall asleep, THC actually disrupts sleep architecture by suppressing REM sleep. Quality sleep is important for consolidating the neural changes that ketamine therapy promotes. Disrupted sleep may reduce treatment effectiveness.

Motivational and cognitive effects. Regular THC use can affect motivation, executive function, and emotional processing in ways that may interfere with the active engagement that makes ketamine therapy most effective. The integration work between sessions -- therapy, journaling, lifestyle changes -- benefits from cognitive clarity.

CBD: A Different Conversation

CBD deserves separate consideration because its pharmacological profile is substantially different from THC.

CBD does not produce psychoactive effects, does not significantly impair cognition, and has a generally favorable safety profile. Some research suggests CBD may have anti-inflammatory and neuroprotective properties that could theoretically complement ketamine therapy rather than interfere with it.

However, CBD does interact with liver enzymes (particularly CYP3A4 and CYP2D6) that are involved in metabolizing ketamine. High-dose CBD could potentially alter ketamine's metabolism, affecting its blood levels and duration of action. This pharmacokinetic interaction is worth noting, even if its clinical significance at typical CBD doses is likely modest.

My position on CBD during ketamine therapy is more nuanced than on THC. Low-dose CBD is probably low-risk, but I still recommend discussing it with your prescribing clinician and ideally pausing during the initial treatment phase when we are establishing your response to ketamine.

My Clinical Recommendation: Pause During Treatment

My recommendation to patients is straightforward: pause all cannabis use during your initial ketamine treatment series -- typically the first four to six weeks.

I frame this as a "pause" rather than a permanent change because I respect patient autonomy and recognize that cannabis serves legitimate purposes for many patients. But during the critical initial treatment window, I want to give ketamine the clearest possible path to do its work.

Here is the reasoning:

Isolating treatment response. If you are using cannabis and ketamine simultaneously and your depression improves (or does not improve), we cannot determine ketamine's actual contribution. Pausing cannabis gives us clean data about how ketamine works for you specifically.

Maximizing the neuroplasticity window. The initial treatment series is when the most intensive neural rewiring occurs. Removing anything that might interfere with this process -- even theoretically -- gives you the best shot at a strong treatment response.

Establishing a new baseline. Many patients who use cannabis regularly have not experienced their brain without it in a long time. Pausing allows both you and your clinician to see what your symptoms look like without cannabis modulation, which provides valuable clinical information.

Avoiding confounding side effects. If you experience nausea, cardiovascular changes, or psychological distress during a ketamine session, knowing that cannabis is not a contributing factor simplifies clinical decision-making.

What If You Use Cannabis Medicinally?

If cannabis was prescribed or recommended by a physician for a specific condition -- chronic pain, seizure disorder, spasticity, or another indication -- this requires a more individualized discussion. Abruptly stopping a medication that manages a real condition has its own risks and consequences.

In these cases, I work with the patient and their prescribing physician to develop a plan that balances the needs of their existing condition with the optimization of ketamine therapy. This might involve temporary dose reduction, switching to CBD-only products, or adjusting timing to minimize overlap with ketamine sessions.

The point is that I will never insist a patient suffer from an untreated condition in the name of theoretical treatment optimization. Clinical medicine is about balancing real tradeoffs, not applying rigid rules.

Be Honest With Your Treatment Team

The most important message in this article is this: be completely transparent with your Tovani Health clinician about your cannabis use. Frequency, form (smoking, edibles, tinctures), THC content, CBD content, and the reasons you use it are all relevant clinical information.

No one at Tovani Health will judge you for using cannabis. We will not refuse treatment or lecture you. But we need accurate information to make good clinical decisions and keep you safe. If your clinician does not know you are using cannabis, they cannot account for it in your treatment plan.

After Your Initial Treatment Course

Once you have completed your initial treatment series and we have established a clear picture of how you respond to ketamine therapy, the conversation about cannabis use becomes more flexible. If you achieved a good response during the cannabis-free period, reintroducing it and monitoring for any change in your symptoms provides useful information.

Some patients find that as their depression lifts through ketamine therapy, their desire to use cannabis naturally decreases. Others choose to reintroduce it for specific purposes. Either path is reasonable, and your ongoing clinician relationship with Tovani Health supports continued monitoring and adjustment.

Ready to Start Treatment?

If you have questions about cannabis use, medication interactions, or any other aspect of ketamine therapy, our evaluation process is designed to address them thoroughly. We take an honest, practical approach to every aspect of your treatment -- including the substances you use and the lifestyle factors that affect your care.

Check your eligibility today to start a confidential evaluation with Tovani Health. Bring your questions, bring your honesty, and let us help you determine the best path forward for your mental health.